Oxular Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Acquired/​Merged

  • Employees
  • 13

Employees

  • Latest Deal Type
  • M&A

Oxular General Information

Description

Operator of a retinal therapeutics company intended to offer retinal disease treatment. The company provides tissue-specific delivery of potent drug products to address multiple pathophysiological pathways of retinal diseases such as age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and cystoid macular edema, enabling patients to increase the cure's effectiveness, reduce its side effects and minimize the frequency of their retinal treatments.

Contact Information

Website
www.oxular.com
Formerly Known As
Precision Ocular
Ownership Status
Acquired/Merged
(Operating Subsidiary)
Financing Status
Formerly VC-backed
Corporate Office
  • One London Wall
  • 6th Floor
  • London EC2Y 5EB
  • England, United Kingdom
+44 01865
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Parent Company
Regeneron Pharmaceuticals
Vertical(s)
LOHAS & Wellness, TMT, HealthTech, Life Sciences
Corporate Office
  • One London Wall
  • 6th Floor
  • London EC2Y 5EB
  • England, United Kingdom
+44 01865

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Oxular Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
10. Merger/Acquisition 02-Jan-2025 Completed Clinical Trials - Phase 2
9. Grant 01-Dec-2021 Completed Clinical Trials - Phase 2
8. Later Stage VC (Series A1) 01-Mar-2021 Completed Clinical Trials - Phase 2
7. Later Stage VC 30-Apr-2020 Completed Clinical Trials - Phase 2
6. Later Stage VC 20-Sep-2019 Completed Clinical Trials - Phase 2
5. Grant 01-Jul-2019 Completed Clinical Trials - Phase 2
4. Early Stage VC 29-Jun-2018 Completed Clinical Trials - Phase 2
3. Grant 01-Mar-2018 Completed Clinical Trials - Phase 2
2. Grant 01-Jan-2017 $860K $20.8M Completed Clinical Trials - Phase 2
1. Early Stage VC (Series A) 19-Jul-2016 $20.8M $20.8M Completed Clinical Trials - Phase 2
To view Oxular’s complete valuation and funding history, request access »

Oxular Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
A1 Preferred
A1 Preferred
A Preferred
A Preferred 39,720 $1.386079 $321.57 $321.57 1x $321.57 25.8%
Ordinary 88 $1.386079 $321.57 $321.57 1x $321.57 0.06%
To view Oxular’s complete cap table history, request access »

Oxular Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Operator of a retinal therapeutics company intended to offer retinal disease treatment. The company provides tissue-spec
Drug Discovery
London, United Kingdom
13 As of 2025

Cambridge, United Kingdom
 

London, United Kingdom
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Oxular Competitors (2)

One of Oxular’s 2 competitors is Exonate, a Venture Capital-Backed company based in Cambridge, United Kingdom.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Exonate Venture Capital-Backed Cambridge, United Kingdom
Gyroscope Formerly VC-backed London, United Kingdom
You’re viewing 2 of 2 competitors. Get the full list »

Oxular Patents

  • 70

    Total Documents Applications and Grants

  • Total Patents Families

  • 49

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Oxular Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
GB-201917493-D0 Methods for the treatment of uveal melanoma Inactive 29-Nov-2019
AU-2020391996-A1 Pharmaceutical compositions and formulations for the treatment of retinoblastoma Inactive 29-Nov-2019
US-20220409560-A1 Pharmaceutical compositions, formulations and methods for the treatment of retinoblastoma Pending 29-Nov-2019
EP-4065118-A2 Pharmaceutical compositions and formulations for the treatment of retinoblastoma Inactive 29-Nov-2019
GB-201917487-D0 Methods for the treatment of retinoblastoma Inactive 29-Nov-2019 A61K31/167
To view Oxular’s complete patent history, request access »

Oxular Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Oxular Former Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
Bespak Corporation Minority
Forbion Venture Capital Minority
Hovione Corporation Minority
IP Group Venture Capital Minority
Innovate UK Government
You’re viewing 5 of 9 investors. Get the full list »

Ready to get started?

Request a free trial

Oxular FAQs

  • When was Oxular founded?

    Oxular was founded in 2014.

  • Where is Oxular headquartered?

    Oxular is headquartered in London, United Kingdom.

  • What is the size of Oxular?

    Oxular has 13 total employees.

  • What industry is Oxular in?

    Oxular’s primary industry is Drug Discovery.

  • Is Oxular a private or public company?

    Oxular is a Private company.

  • What is Oxular’s current revenue?

    The current revenue for Oxular is .

  • How much funding has Oxular raised over time?

    Oxular has raised $67M.

  • Who are Oxular’s investors?

    Bespak, Forbion, Hovione, IP Group, and Innovate UK are 5 of 9 investors who have invested in Oxular.

  • Who are Oxular’s competitors?

    Exonate and Gyroscope are competitors of Oxular.

  • When was Oxular acquired?

    Oxular was acquired on 02-Jan-2025.

  • Who acquired Oxular?

    Oxular was acquired by Regeneron Pharmaceuticals.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »